COMMUNIQUÉS West-GlobeNewswire

Noah Medical Announces Collaboration to Advance Imaging in Robotic-Assisted Bronchoscopy
27/08/2026
Compatibility between the Galaxy™ System and premium GE HealthCare OEC C-arms reflects collaboration to expand access to advanced lung diagnostics SAN JOSE, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Noah Medical today [...]
Cardurion Pharmaceuticals Announces Late-Breaking Presentation of Phase 2 Results for Tovinontrine (CRD-750), a PDE9 Inhibitor, in Heart Failure
27/08/2026
Results from two Phase 2 clinical trials assessing tovinontrine in both major types of chronic heart failure will be presented at the Heart Failure Society of America annual scientific meeting BURLINGTON, Mass., Aug. 27 [...]
HealthEquity Reports Second Quarter Ended July 31, 2026 Financial Results
27/08/2026
Highlights of the second quarter include: Net income increased 10% to $65.6 million , and net income margin increased to 19% from 18% last year. Adjusted EBITDA increased 11% to $167.0 million , and Adjusted EBITDA [...]
Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes
27/08/2026
Research Shows that Patients with PSVT Experience a Substantial Burden Between Episodes, with Negative Impacts on Anxiety, Daily Activities, Sleep, and Work MONTREAL and CHARLOTTE, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE [...]
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
27/08/2026
– Per-protocol interim statistical power analysis confirms no additional patients are recommended for full enrollment – – Second pivotal Phase 3 trial (COVE-3) has already exceeded 50% of current target enrollment, with [...]
Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor
27/08/2026
HAIFA, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri”), a biotechnology company, leveraging its proprietary three-dimensional ("3D") cell expansion platform across two [...]
HighLife Receives CE Mark Approval for Clarity Valve, the Next-Generation Valve for the HighLife TMVR System
27/08/2026
Paris, France - August 27, 2026 – HighLife SAS, a medical technology company focused on the development of a unique transcatheter mitral valve replacement (“TMVR”) system to treat patients suffering from mitral [...]
Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference
27/08/2026
DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
Orion Corporation to commence acquisition of own shares for its share-based incentive plans
27/08/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 27 AUGUST 2026 at 13.00 EEST Orion Corporation to commence acquisition of own shares for its share-based [...]
HighLife Receives CE Mark Approval for Clarity Valve, the Next-Generation Valve for the HighLife TMVR System
27/08/2026
Paris, France - August 27, 2026 – HighLife SAS, a medical technology company focused on the development of a unique transcatheter mitral valve replacement (“TMVR”) system to treat patients suffering from mitral [...]
Osivax and GC Biopharma Enter Strategic Collaboration to Develop a Next-Generation Influenza Vaccine Combining OVX836 and GC FLU
27/08/2026
Combines Osivax's proprietary OVX836 T-cell vaccine and technology with GC Biopharma's marketed influenza vaccine and worldwide manufacturing expertise Positions Osivax as the global development lead for a [...]
hVIVO acquires CRS Berlin, expanding expertise into dermatology and women's health markets
27/08/2026
London, UK – 27 August 2026 , hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces the acquisition of CRS Clinical [...]
A decade of profitability provides foundation for CLINUVEL’s U.S. expansion
27/08/2026
MELBOURNE, Australia and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced its tenth consecutive annual profit and further rise in free cash in the [...]
Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma
27/08/2026
Press Release Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma FDA sets Prescription Drug User Fee Act (PDUFA) review response date by 30 April 2027 Two NDAs filed in major markets, with commercial partners [...]
Nicox annonce avril 2027 comme date PDUFA pour NCX 470 dans le traitement du glaucome
27/08/2026
Communiqué de presse Nicox annonce avril 2027 comme date PDUFA pour NCX 470 dans le traitement du glaucome La FDA a fixé la date de réponse à l’examen de la NDA dans le cadre du Prescription Drug User Fee Act (PDUFA) au [...]
IBA reports Half Year 2026 results, on track with its improved profitability trajectory
27/08/2026
Louvain-la-Neuve, Belgium, 27 August 2026, 7 a.m. - IBA (Ion Beam Applications S.A.), today announces its consolidated results for the first half of 2026, with performance on track with FY 2026 guidance and continued [...]
IBA publie ses résultats semestriels 2026, et confirme sa trajectoire d’amélioration de la rentabilité
27/08/2026
Louvain-La-Neuve, Belgique, 27 août 2026, 7h00 - IBA (Ion Beam Applications S.A.), annonce aujourd’hui ses résultats consolidés pour le premier semestre 2026, avec une performance conforme aux prévisions pour l’exercice [...]
Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates
27/08/2026
SHANGHAI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Mesoblast Reports Substantial Revenue Growth to US$120M
27/08/2026
RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: [...]

Pages